First Manhattan
CTMX icon

First Manhattan’s CytomX Therapeutics CTMX Stock Holding History

First Manhattan’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-345,451
Closed -$2.3M – 1340
2020
Q3 		$2.3M Sell
345,451
-307,105
-47% -$2.28M 0.01% 282
2020
Q2 		$5.43M Sell
652,556
-142,368
-18% -$1.32M 0.03% 206
2020
Q1 		$6.1M Sell
794,924
-183,938
-19% -$1.28M 0.04% 187
2019
Q4 		$8.13M Buy
+978,862
New +$6.6M 0.04% 186
2019
Q2 		– Sell
-322,000
Closed -$3.46M – 1374
2019
Q1 		$3.46M Buy
+322,000
New +$4.76M 0.02% 278

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan's CTMX Position: Q4 2020 in Review

First Manhattan sold out of CytomX Therapeutics (CTMX) in Q4 2020, closing a stake of 345,451 shares — an estimated $2.3M sold.

First Manhattan first reported a position in CTMX in Q1 2019 and held it in 5 quarters. The position peaked at $8.13M in Q4 2019. 126 funds tracked by Wall St. Rank hold CTMX as of Q4 2020.

  • First Manhattan reported no remaining CytomX Therapeutics position as of Q4 2020 after selling out during the quarter.
  • First Manhattan sold 345,451 CytomX Therapeutics shares in Q4 2020, an estimated $2.3M.
  • First Manhattan first reported a position in CytomX Therapeutics in Q1 2019 and held it in 5 quarters.
  • First Manhattan's CytomX Therapeutics position peaked at $8.13M in Q4 2019.
  • 126 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2020.

Based on First Manhattan's 13F filing for Q4 2020, filed 16 Feb 2021.